❌

Normal view

FoodMonitor: Benchmarking MLLMs for Explainable Compliance Analysis

arXiv:2605.24503v1 Announce Type: cross Abstract: As AI-powered compliance monitoring becomes increasingly important in public governance and industrial safety, the ability to provide verifiable evidence and traceable accountability signals is essential. However, existing video anomaly detection datasets focus on event-level binary classification, lacking the rule-driven, explainable analysis required for real-world compliance scenarios. We introduce FoodMonitor, a benchmark for explainable compliance analysis in commercial kitchen surveillance. FoodMonitor comprises 477 video clips with 3,307 violation annotations across a dual-channel design covering both person-level and environment-level violations. Each annotation specifies which rule was violated, what non-compliant behavior occurred, and who committed it with frame-level bounding boxes. We establish a unified evaluation protocol with a two-stage matching mechanism that separately assesses spatial localization and semantic understanding, along with a composite metric ($C_{\text{score}}$) that balances environment and person detection performance. Systematic evaluation of several state-of-the-art multimodal large language models reveals that the best-performing model achieves only 0.360 $C_{\text{score}}$, with spatial localization and fine-grained rule understanding emerging as the primary bottlenecks. Our analysis identifies two distinct failure modes: localization-dominated errors and semantics-dominated errors, providing diagnostic insights for future model development.

Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma: The Systemic Execution Hub of Metastasis

18 May 2026 at 18:00

Pharmacol Res. 2026 May 17:108253. doi: 10.1016/j.phrs.2026.108253. Online ahead of print.

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) exemplifies early systemic dissemination, with circulating tumor cells (CTCs) at its core. We advance a unified conceptual framework that positions CTCs as the systemic execution hub of PDAC metastasis, dynamic entity that coordinates the metastatic cascade via four cardinal functions: Seeding, Adapting, Engineering, and Signaling. Integrating eco-evolutionary dynamics, this hub actively drives phenotypic selection, niche remodeling, and immune evasion, while providing real-time biologic intelligence through liquid biopsy. Robust clinical correlation has not yet translated into routine practice because of technical variability, biological complexity, and a lack of interventional evidence. We therefore propose an evidence-driven, phased roadmap: grounded in prospective clinical cohort data, progressing from immediate multi-center technical standardization and pragmatic trials, such as minimal residual disease (MRD)-triggered salvage therapy, to mid-term biomarker-driven adjuvant trials and long-term integration into multimodal liquid biopsy ecosystems, aimed at intercepting this execution hub. By reframing CTCs from correlative indicators to actionable therapeutic targets and dynamic sentinels, this framework charts a path toward transforming the management of this recalcitrant systemic disease.

PMID:42150733 | DOI:10.1016/j.phrs.2026.108253

Refined immune-based molecular subtypes of gastric cancer: Integrating mismatch repair status and tumor microenvironment for enhanced immunotherapy prediction

18 May 2026 at 18:00

Chin J Cancer Res. 2026 Apr 30;38(2):234-251. doi: 10.21147/j.issn.1000-9604.2026.02.09.

ABSTRACT

OBJECTIVE: Gastric cancer (GC) is heterogeneous, and current mismatch repair (MMR)-based classifications incompletely predict response to immune checkpoint inhibitors (ICIs).

METHODS: RNA sequencing (RNA-seq) and immune infiltration profiles from 189 resected GC were used to derive four refined immune-MMR subtypes (R1-R4) by integrating MMR status, survival, and tumor microenvironment (TME) features. Multi-omics profiling and pathway analysis defined subtype biology. External transcriptomic cohorts and an ICI-treated cohort were classified with Nearest Template Prediction (NTP). Immune response-associated genes were identified from responder vs. non-responder comparisons within the ICI-sensitive subtype and validated by multiplex immunohistochemistry (mIHC).

RESULTS: R1 showed the best prognosis and highest immunotherapy response with objective response rate (ORR) 54.5%, while R4 had the worst prognosis. R2 represented an immune-unresponsive deficient mismatch repair (dMMR) subset, and R3 captured an immune-active proficient mismatch repair (pMMR) subgroup with moderate therapy sensitivity. Multi-omics integration revealed subtype-specific pathways (e.g., ECM remodeling in R1, metabolic reprogramming in R2). Reclassification of pMMR tumors based on transcriptional similarity to R1 identified a New R3 subset with enhanced immune features and higher ICI response. Eight immune response-associated genes (e.g., CXCL10, CXCL11, ELN, GAD1, IL32, MT1E, OR2I1P, SLC3A1) were identified and validated by mIHC for predictive relevance.

CONCLUSIONS: This immune-based molecular framework refines risk stratification beyond conventional MMR categories, identifies ICI-sensitive subsets among both dMMR and pMMR tumors, and proposes candidate biomarkers for patient selection.

PMID:42147371 | PMC:PMC13171420 | DOI:10.21147/j.issn.1000-9604.2026.02.09

❌